Compare
Beam Therapeutics Inc. vs Monte Rosa Therapeutics, Inc. vs Atara Biotherapeutics, Inc. vs Ginkgo Bioworks Holdings, Inc.
| Latest fiscal year | Beam Therapeutics Inc. BEAM | Monte Rosa Therapeutics, Inc. GLUE | Atara Biotherapeutics, Inc. ATRA | Ginkgo Bioworks Holdings, Inc. DNA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $139.74M | $123.67M | $120.77M | $170.16M |
| Revenue growth (YoY) | +120.0% | +63.5% | -6.3% | -25.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -274.6% | -43.8% | 29.7% | -185.3% |
| Net margin | -57.2% | -31.2% | 27.1% | -183.8% |
| Net income | -$79.99M | -$38.63M | $32.69M | -$312.76M |
| EPS (Diluted) | -$0.81 | n/a | $2.57 | -$5.64 |
| Operating cash flow | -$345.10M | -$22.80M | -$50.94M | -$171.06M |
| Free cash flow | -$360.05M | -$27.50M | -$50.94M | -$178.72M |
| Cash & equivalents | $294.94M | $129.88M | $8.48M | $167.20M |
| Total assets | $1.48B | $448.66M | $20.23M | $1.12B |
| Total liabilities | $242.82M | $215.60M | $58.74M | $611.11M |
| Shareholders' equity | $1.24B | $233.06M | -$38.50M | $508.59M |
| Return on year-end equity | -6.5% | -16.6% | n/a | -61.5% |
| Shares outstanding | 101.75M | 65.54M | 7.32M | 58.21M |
Revenue, most recent five fiscal years
| Fiscal year | Beam Therapeutics Inc. | Monte Rosa Therapeutics, Inc. | Atara Biotherapeutics, Inc. | Ginkgo Bioworks Holdings, Inc. |
|---|---|---|---|---|
| Latest | $139.74M Ended 2025-12-31 | $123.67M Ended 2025-12-31 | $120.77M Ended 2025-12-31 | $170.16M Ended 2025-12-31 |
| 1 year earlier | $63.52M Ended 2024-12-31 | $75.62M Ended 2024-12-31 | $128.94M Ended 2024-12-31 | $227.04M Ended 2024-12-31 |
| 2 years earlier | $377.71M Ended 2023-12-31 | $0 Ended 2023-12-31 | $8.57M Ended 2023-12-31 | $251.46M Ended 2023-12-31 |
| 3 years earlier | $60.92M Ended 2022-12-31 | n/a | $63.57M Ended 2022-12-31 | $477.71M Ended 2022-12-31 |
| 4 years earlier | $51.84M Ended 2021-12-31 | n/a | n/a | $313.84M Ended 2021-12-31 |